Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Trefoil Therapeutics reports new findings from FECD therapy trial

Trefoil Therapeutics reports new findings from FECD therapy trial

The results indicated TTHX1114 activated dose-dependent response in corneal oedema resolution and improved BCVA after surgery in all the patients.

Trefoil Therapeutics has reported additional results from the Phase ll STORM trial of TTHX1114  to protect endothelial cells from damage due to cataract surgery in Fuchs endothelial corneal dystrophy (FECD) patients receiving Descemet Stripping Only (DSO).

The results showed that TTHX1114 activated a dose-dependent response in corneal oedema resolution and improved best corrected visual acuity (BCVA) after surgery in all the patients.

The percentage of patients with complete resolution of corneal oedema in the high-dose groups at 28 days post-surgery was similar to patients with DSO in comparison with those with DSO and cataract surgery.

Furthermore, at 28 days following surgery, the percentage of patients who recovered from adequate BCVA was also similar between these patient groups, showing 58% of the DSO only patients as against 61% of the DSO and cataract surgery patients.

Trefoil Therapeutics president and CEO David Eveleth said: “Corneal endothelial diseases, like FECD, affect millions of Americans, and today there are limited treatment options.

“Therefore, it is imperative that we continue to explore new therapies to allow these patients to retain functional vision.

“It is exciting to see TTHX1114 perform well in controlling post-surgical oedema in at-risk patients undergoing cataract surgery.”

In September 2022, Trefoil announced positive Phase ll study data of TTHX1114, indicating corneal regeneration and vision recovery following DSO surgery.

Meanwhile, in January this year, Trefoil announced the dosing of first subject in the Phase I trial, completing the Phase l epithelial trial in March.

Phase I examined the safety and dosing of topical TTHX1114 to minimise the duration and effect of corneal epithelial defects.

April 25, 2023


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies